MedTrace Logo

A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy

NCT00344760 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-05-11

No results posted yet for this study

Summary

We hypothesize that using a potent antiretroviral such as Enfuvirtide during the induction phase of HAART therapy will lead to faster clearance of virus and infected cells, and lower number of minority variant HIV-1 strains.

Conditions

  • HIV Infections

Interventions

DRUG

Enfuvirtide

subcutaneously twice a day

DRUG

Efavirenz, lamivudine, and tenofovir

Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily

Sponsors & Collaborators

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Ronald B Reisler, MD, MPH · University of Maryland, School of Medicine, Department of Infectious Disease

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00344760 on ClinicalTrials.gov